Ensign Peak Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Ensign Peak Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105M	Sell	210,483 -4,682	-2%	-$2.07M	0.17%	109
2026 Q1	$96.1M	Sell	215,165 -88,619	-29%	-$41.3M	0.18%	114
2025 Q4	$138M	Sell	303,784 -8,214	-3%	-$3.54M	0.24%	85
2025 Q3	$122M	Buy	311,998 +134,964	+76%	+$56.4M	0.2%	105
2025 Q2	$78.8M	Sell	177,034 -57,687	-25%	-$26.6M	0.13%	143
2025 Q1	$114M	Sell	234,721 -40,361	-15%	-$18.8M	0.22%	96
2024 Q4	$111M	Buy	275,082 +97,611	+55%	+$45.2M	0.2%	103
2024 Q3	$82.5M	Sell	177,471 -6,233	-3%	-$2.99M	0.15%	125
2024 Q2	$86.1M	Sell	183,704 -40,789	-18%	-$17.7M	0.16%	115
2024 Q1	$93.8M	Sell	224,493 -436,034	-66%	-$184M	0.17%	115
2023 Q4	$269M	Sell	660,527 -94,975	-13%	-$35.1M	0.53%	42
2023 Q3	$263M	Sell	755,502 -11,990	-2%	-$4.19M	0.56%	39
2023 Q2	$270M	Buy	767,492 +18,132	+2%	+$6.11M	0.55%	42
2023 Q1	$236M	Buy	749,360 +321,980	+75%	+$96.6M	0.51%	50
2022 Q4	$123M	Buy	427,380 +31,689	+8%	+$9.66M	0.28%	89
2022 Q3	$115M	Buy	395,691 +30,810	+8%	+$8.86M	0.28%	86
2022 Q2	$103M	Buy	364,881 +31,572	+9%	+$8.45M	0.24%	100
2022 Q1	$87M	Buy	333,309 +37,631	+13%	+$8.93M	0.18%	113
2021 Q4	$64.9M	Sell	295,678 -151,534	-34%	-$29.5M	0.12%	152
2021 Q3	$81.1M	Sell	447,212 -158,321	-26%	-$30.9M	0.17%	128
2021 Q2	$122M	Buy	605,533 +59,685	+11%	+$12.5M	0.25%	102
2021 Q1	$117M	Buy	545,848 +4,116	+0.8%	+$904K	0.25%	101
2020 Q4	$128M	Buy	541,732 +40,970	+8%	+$9.4M	0.29%	87
2020 Q3	$136M	Sell	500,762 -122,808	-20%	-$33.9M	0.34%	66
2020 Q2	$181M	Sell	623,570 -175,878	-22%	-$47.7M	0.49%	49
2020 Q1	$190M	Sell	799,448 -10,669	-1%	-$2.45M	0.64%	37
2019 Q4	$177M	Buy	+810,117	New	+$164M	0.47%	54

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ensign Peak Advisors's VRTX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q2 2026, selling an estimated $2.07M and leaving 210,483 shares worth $105M. The position accounts for 0.17% of the portfolio, ranked #109.

Ensign Peak Advisors first reported a position in VRTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $270M in Q2 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Ensign Peak Advisors held 210,483 shares of Vertex Pharmaceuticals worth $105M as of Q2 2026.
Ensign Peak Advisors sold 4,682 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.07M.
Vertex Pharmaceuticals made up 0.17% of Ensign Peak Advisors's portfolio in Q2 2026, its #109 holding.
Ensign Peak Advisors first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
Ensign Peak Advisors's Vertex Pharmaceuticals position peaked at $270M in Q2 2023.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.